16 September 2026 editorial review · Item
Sinocare iCan i6: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Sinocare iCan i6
Scope and findings: Added in the second discovery pass. A smaller iCan CGM family commercialized in China, with15-day wear and three-minute updates. The international page explicitly excludes sales in the UK and many EU countries; those markets are not marked available. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
- Sinocare iCan i6 specifications and regional sales restrictions
- Sinocare product history and i3/i6 launch distinctions
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.